Aditxt, Inc. - ADTX STOCK NEWS

Aditxt, Inc. (NASDAQ: ADTX) has been featured by FedEx in a video presentation highlighting its AditxtScore™ technology, which helps monitor immune responses to COVID-19. The company collaborates with FedEx to ensure timely delivery of blood samples critical for processing and generating personalized immune profiles using proprietary technologies. Aditxt aims to enhance understanding of immune status, assisting healthcare professionals in making informed vaccination decisions.

Aditxt, Inc. (NASDAQ: ADTX) has confirmed compliance with Nasdaq's minimum bid price and stockholders' equity requirements. This compliance follows a recent reverse stock split and a successful $20 million public offering. CEO Amro Albanna highlighted that these steps are crucial for the company's ongoing programs, which include AditxtScore™, Adimune™, and Adivir™, aimed at monitoring and modulating the immune system. Aditxt continues to develop technologies to personalize immune profiles and address organ rejection, autoimmune diseases, and allergies.

Aditxt, Inc. (Nasdaq: ADTX) has completed a reverse stock split and closed a $20 million public offering, crucial for advancing its key programs: AditxtScore™, Adimune™, and Adivir™. The reverse split positions the company for compliance with Nasdaq requirements, with 3,708,647 shares outstanding. AditxtScore™ is seeing revenue growth, while Adimune™ is preparing for clinical trials and Adivir™ holds potential revenue from a partnership with Cellvera. This development could lead to improved financial health and product advancement in immune system technologies in 2023.

Aditxt, Inc. (Nasdaq: ADTX) has successfully closed a public offering, selling 3,333,333 shares of common stock and warrants at a combined price of $6.00 each. The gross proceeds from the offering total approximately $20.0 million, which will be utilized for operating expenses and working capital. The warrants, with an exercise price of $6.00, are immediately exercisable and expire in five years. H.C. Wainwright & Co. served as the exclusive placement agent for this transaction.

Aditxt, Inc. (Nasdaq: ADTX) announced a public offering of 3,333,333 shares of common stock and associated warrants at $6.00 per unit, aiming to raise approximately $20 million. The warrants, with an exercise price of $6.00, are exercisable immediately and expire in five years. Proceeds will fund general corporate expenses, including R&D and potential acquisitions, although no current commitments are in place. Closing of the offering is expected around September 20, 2022, pending customary conditions. H.C. Wainwright & Co. is the exclusive placement agent.

Aditxt, Inc. (Nasdaq: ADTX) announced a 1-for-50 reverse stock split effective September 13, 2022. The split aims to comply with Nasdaq's $1.00 per share minimum bid price requirement. Post-split, approximately 1,156,674 shares will be outstanding with the CUSIP number 007025505. The reverse split was approved by stockholders during a special meeting on September 7, 2022. Trading on a post-split basis will begin on September 14, 2022. Aditxt focuses on immune system monitoring and modulation technologies.

Aditxt, Inc. (NASDAQ: ADTX) announces positive results from a toxicology study for its immunotherapeutic drug ADI™-100, aimed at treating autoimmune diseases and organ transplantation rejection. The study demonstrated a robust safety profile with no premature deaths or adverse clinical signs. These findings will support an upcoming Investigational New Drug (IND) application. Aditxt's commitment to advancing innovative solutions in the biotech sector is emphasized by the encouraging results, positioning ADI™-100 for potential human trials.

On June 14, 2022, Premier Medical Laboratory Services (PMLS) announced the addition of AditxtScore™ to its testing services, aimed at providing insights into patients' immunity profiles against SARS-CoV-2. The test assesses multiple antibodies and their effectiveness, enabling individuals to make informed decisions on vaccinations and risk mitigation. PMLS, a CAP accredited lab with extensive COVID-19 testing experience, emphasizes the importance of monitoring immunity trends as new variants emerge. AditxtScore™ can also help employers optimize testing protocols and reduce workplace disruptions.

Aditxt, Inc. (NASDAQ: ADTX) has announced a multiyear partnership with GRS, an affiliate of Guthy-Renker, to enhance awareness of its AditxtScore™ Immune Monitoring Platform. This collaboration aims to produce and broadcast TV commercials to boost visibility among consumers and healthcare providers. The AditxtScore™ technology, which provides insights into immune status related to COVID-19, is now fully operational in Richmond, VA. Aditxt's partnership with GRS leverages extensive marketing experience to facilitate a national rollout of AditxtScore™.